Blog

$Andrius Žučenka: Stop by at our EHA2024 poster on relapsed/refractory AML$

Photo of Andrius Žučenka from vjhemonc.com

Jun 16, 2024, 02:39

Andrius Žučenka: Stop by at our EHA2024 poster on relapsed/refractory AML

Andrius Žučenka, Head of The Department of Specialized Care For Immunocompromised Patients at VUL Santaros Klinikos, shared a post on X:

“Please stop by at our EHA2024 poster P1325 with the results of the non-intensive, targeted therapy-based preconditioning regimens followed by standard conditioning and alloSCT in relapsed/refractory AML/HR-MDS patients with active disease (including TP53m/post-Ven).”

$Andrius Žučenka: Stop by at our EHA2024 poster on relapsed/refractory AML$

Source: Andrius Žučenka/X

active disease alloSCT Andrius Žučenka cancer EHA2024 HR-MDS OncoDaily Oncology P1325 post-Ven preconditioning regimens R/R AML standard conditioning targeted therapy TP53m

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage